<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Orphazyme A S ADR (NASDAQ:ORPH) shares are trading lower by 42% at $8.41 Friday morning after the company announced it received a Complete Response Letter from the FDA for its treatment for Niemann-Pick Disease Type C and also cut its FY2021 outlook. See Also: Orphazyme Wild Party At Risk As FDA Rejects Its Rare Neurodegenerative Disease Drug
...read full article on Benzinga
